S&P 500   3,307.27 (-0.44%)
DOW   29,021.63 (-0.56%)
QQQ   223.53 (-0.15%)
AAPL   317.33 (-0.12%)
FB   220.32 (-0.45%)
MSFT   165.95 (+0.15%)
GOOGL   1,481.77 (-0.16%)
AMZN   1,879.20 (-0.44%)
NVDA   250.05 (+0.00%)
BABA   218.25 (-1.85%)
MU   59.47 (+0.51%)
GE   11.73 (+3.17%)
TSLA   574.76 (+0.91%)
AMD   51.08 (-0.68%)
T   38.66 (-0.97%)
ACB   2.09 (+2.45%)
F   9.03 (-1.42%)
NFLX   336.07 (+3.09%)
DIS   141.73 (-1.58%)
GILD   63.21 (-0.35%)
S&P 500   3,307.27 (-0.44%)
DOW   29,021.63 (-0.56%)
QQQ   223.53 (-0.15%)
AAPL   317.33 (-0.12%)
FB   220.32 (-0.45%)
MSFT   165.95 (+0.15%)
GOOGL   1,481.77 (-0.16%)
AMZN   1,879.20 (-0.44%)
NVDA   250.05 (+0.00%)
BABA   218.25 (-1.85%)
MU   59.47 (+0.51%)
GE   11.73 (+3.17%)
TSLA   574.76 (+0.91%)
AMD   51.08 (-0.68%)
T   38.66 (-0.97%)
ACB   2.09 (+2.45%)
F   9.03 (-1.42%)
NFLX   336.07 (+3.09%)
DIS   141.73 (-1.58%)
GILD   63.21 (-0.35%)
S&P 500   3,307.27 (-0.44%)
DOW   29,021.63 (-0.56%)
QQQ   223.53 (-0.15%)
AAPL   317.33 (-0.12%)
FB   220.32 (-0.45%)
MSFT   165.95 (+0.15%)
GOOGL   1,481.77 (-0.16%)
AMZN   1,879.20 (-0.44%)
NVDA   250.05 (+0.00%)
BABA   218.25 (-1.85%)
MU   59.47 (+0.51%)
GE   11.73 (+3.17%)
TSLA   574.76 (+0.91%)
AMD   51.08 (-0.68%)
T   38.66 (-0.97%)
ACB   2.09 (+2.45%)
F   9.03 (-1.42%)
NFLX   336.07 (+3.09%)
DIS   141.73 (-1.58%)
GILD   63.21 (-0.35%)
S&P 500   3,307.27 (-0.44%)
DOW   29,021.63 (-0.56%)
QQQ   223.53 (-0.15%)
AAPL   317.33 (-0.12%)
FB   220.32 (-0.45%)
MSFT   165.95 (+0.15%)
GOOGL   1,481.77 (-0.16%)
AMZN   1,879.20 (-0.44%)
NVDA   250.05 (+0.00%)
BABA   218.25 (-1.85%)
MU   59.47 (+0.51%)
GE   11.73 (+3.17%)
TSLA   574.76 (+0.91%)
AMD   51.08 (-0.68%)
T   38.66 (-0.97%)
ACB   2.09 (+2.45%)
F   9.03 (-1.42%)
NFLX   336.07 (+3.09%)
DIS   141.73 (-1.58%)
GILD   63.21 (-0.35%)
Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

NASDAQ:IMPV - Imperva Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume905,414 shs
Market Capitalization$1.98 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.09
Imperva, Inc engages in the development, market, sale, and support of cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. The company's SecureSphere product line provides database, file, and Web application security in various data centers, including on-premises data centers, as well as in private, public, and hybrid cloud computing environments. Read More…

Industry, Sector and Symbol

Industry Prepackaged software
Sub-IndustrySystems Software
SectorComputer and Technology
Current SymbolNASDAQ:IMPV
CUSIP45321L10
Phone650-345-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$321.72 million
Book Value$9.26 per share

Profitability

Net Income$22.86 million

Miscellaneous

EmployeesN/A
Market Cap$1.98 billion
Next Earnings DateN/A
OptionableOptionable

Receive IMPV News and Ratings via Email

Sign-up to receive the latest news and ratings for IMPV and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Join a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week.

Imperva (NASDAQ:IMPV) Frequently Asked Questions

What is Imperva's stock symbol?

Imperva trades on the NASDAQ under the ticker symbol "IMPV."

How were Imperva's earnings last quarter?

Imperva Inc (NASDAQ:IMPV) issued its quarterly earnings results on Wednesday, October, 31st. The software maker reported $0.43 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.25. The software maker earned $91.63 million during the quarter, compared to analyst estimates of $89.24 million. Imperva had a negative return on equity of 5.62% and a negative net margin of 8.00%. View Imperva's Earnings History.

Has Imperva been receiving favorable news coverage?

News articles about IMPV stock have trended somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Imperva earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned media headlines about the software maker a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Imperva.

Who are some of Imperva's key competitors?

What other stocks do shareholders of Imperva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Imperva investors own include Intel (INTC), Netflix (NFLX), Cisco Systems (CSCO), Alibaba Group (BABA), Palo Alto Networks (PANW), Broadcom (AVGO), NVIDIA (NVDA), salesforce.com (CRM), Johnson & Johnson (JNJ) and FireEye (FEYE).

Who are Imperva's key executives?

Imperva's management team includes the folowing people:
  • Mr. Christopher S. Hylen, Pres, CEO & Director (Age 58)
  • Ms. Trâm T. Phi, Chief Legal Officer & Chief of Staff (Age 48)
  • Mr. Michael J. Burns, Chief Financial Officer & Treasurer (Age 53)
  • Mr. Aharon Strosberg, VP of Operations
  • Mr. Terry Ray, Chief Technology Officer

How big of a company is Imperva?

Imperva has a market capitalization of $0.00 and generates $321.72 million in revenue each year. The software maker earns $22.86 million in net income (profit) each year or ($0.28) on an earnings per share basis. View Additional Information About Imperva.

What is Imperva's official website?

The official website for Imperva is http://www.imperva.com/.

How can I contact Imperva?

Imperva's mailing address is 3400 BRIDGE PARKWAY, REDWOOD SHORES CA, 94065. The software maker can be reached via phone at 650-345-9000 or via email at [email protected]


MarketBeat Community Rating for Imperva (NASDAQ IMPV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  682 (Vote Outperform)
Underperform Votes:  418 (Vote Underperform)
Total Votes:  1,100
MarketBeat's community ratings are surveys of what our community members think about Imperva and other stocks. Vote "Outperform" if you believe IMPV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMPV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel